Direct separation and quantitative determination of flurbiprofen enantiomers in pharmaceutical formulations

Journal of Liquid Chromatography and Related Technologies

Volumn 26, Issue 4, 2003, Pages 517-527

  Santoro, Maria Inês R M ^a   Singh, Anil K ^a   Kedor Hackmann, Erika R M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chiral liquid chromatography; Enantiomeric separation; Flurbiprofen capsule; Method validation; Quality control

Indexed keywords

CONCENTRATION (PROCESS); CORRELATION METHODS; DRUG PRODUCTS; SAMPLING; SILICA GEL;

BASELINE RESOLUTION;

LIQUID CHROMATOGRAPHY;

FLURBIPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CALIBRATION; CHIRAL CHROMATOGRAPHY; CHROMATOGRAPHY; DRUG CAPSULE; DRUG DETERMINATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STRUCTURE; ENANTIOMER; LIQUID CHROMATOGRAPHY; QUALITY CONTROL; REPRODUCIBILITY; SUSTAINED RELEASE PREPARATION;

EID: 0037283116     PISSN: 10826076     EISSN: None     Source Type: Journal    
DOI: 10.1081/JLC-120017897     Document Type: Article

References (18)

1. Jamali, F.; Collins, D.S.; Berry, B.W.; Molder, S.; Cheung, R.; McColl, K.; Cheung, H. Comparative bioavailability of two flurbiprofen products: Stereoselective verses conventional approach. Biopharma. Drug Dispos. 1991, 12, 435-445.
2. Brune, K.; Geisslinger, G.; Menzel-Soglowek, S. Pure enantiomers of 2-arylpropionic acid: Tools in pain research and improved drugs in rheumatology. J. Clin. Pharmacol. 1992, 32, 944-952.
3. Davies, N.M. Methods of analysis of chiral non-steroidal anti-inflammatory drugs. J. Chromatogr. B 1997, 691, 229-261.
4. Knadler, M.P.; Halls, D. High-performance liquid chromatographic analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine. J. Chromatogr. A 1989, 494, 173-182.
5. VanOverbeke, A.; Baeyens, W.; VanDenbossche, W.; Dewaele, C. Separation of 2-arylpropionic acids on a cellulose-based chiral stationaryphase by RP-HPLC. J. Pharm. Biomed. Anal. 1994, 12, 901-909.
6. Hermansson, J.; Hermansson, I. Dynamic modification of the chiral bonding properties of a chiral-AGP column by organic and inorganic additives-separation of enantiomers of anti-inflammatory drugs. J. Chromatogr. A. 1994, 666, 181-191.
7. Noctor, T.A.G.; Felise, G.; Wainer, I.W. Stereochemical resolution of enantiomeric 2-aryl propionic acid NSAID on human serum albumin based HPLC chiral stationary phase. Chromatographia 1991, 31, 55-59.
8. Allenmark, S.; Andersson, S. Optical resolution of some biologicallyactive compounds by chiral liquid-chromatography on BSA-silica (Resolvosil®) columns. Chirality 1989, 1, 154-160.
9. Chiral Application Guide III; Regis Technologies Inc.: Morton Grove, USA; 77 pp.
10. Pirkle, W.H.; Welch, C.J. An improved chiral stationary phase for the chromatographic-separation of underivatized naproxen enantiomers. J. Liq. Chromatogr. 1992, 15, 1947-1955.
11. Geisslinger, G.; Menzel-Soglowek, S.; Schuster, O.; Brune, K. Stereoselective high-performance liquid chromatographic determination of flurbiprofen in human plasma. J. Chromatogr. A 1992, 573, 163-167.
12. Wilson, W.H. Direct enantiomeric resolution of ibuprofen and flurbiprofen by packed-column SFC. Chirality 1994, 6, 216-219.
13. Santoro, M.I.R.M.; Singh, A.K. Development and regulation of chiral drug substances: An overview on worldwide pharmaceutical guidelines. Brazilian J. Pharm. Sci. 2001, 37, 259-268.
14. ICH Q2B. Validation of Analytical Procedures: Methodology, Nov. 1996, 1-8.
15. Jenke, D.R. Chromatographic method validation: A review of current practices and procedures. II- Guidelines for primary validation parameters. J. Liq. Chromatogr. & Relat. Technol. 1996, 19, 737-757.
16. Official Methods of Analysis of AOAC International, 15th Ed.; AOAC: Arlington, 1990; xvii pp.
17. Singh, A.K.; Kedor-Hackmann, E.R.M.; Santoro, M.I.R.M. Development and validation of a chiral liquid chromatographic method for the determination of atenolol and metoprolol enantiomers in tablet preparations. J. Assoc. Off. Anal. Chem. Int. 2001, 84, 1724-1729.
18. United States Pharmacopeia, 24th Ed.; United States Pharmacopeial Convention: Rockville, 1999; 949-951, 2149-2152.